nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—hepatitis B	0.725	1	CbGaD
Pomalidomide—Musculoskeletal chest pain—Telbivudine—hepatitis B	0.00721	0.042	CcSEcCtD
Pomalidomide—Thalidomide—NFKB1—hepatitis B	0.00611	0.766	CrCbGaD
Pomalidomide—Platelet count decreased—Entecavir—hepatitis B	0.00572	0.0333	CcSEcCtD
Pomalidomide—Bone pain—Adefovir Dipivoxil—hepatitis B	0.00347	0.0202	CcSEcCtD
Pomalidomide—Hyperkalaemia—Adefovir Dipivoxil—hepatitis B	0.00326	0.019	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Telbivudine—hepatitis B	0.00283	0.0165	CcSEcCtD
Pomalidomide—Respiratory tract infection—Lamivudine—hepatitis B	0.00251	0.0146	CcSEcCtD
Pomalidomide—Sepsis—Telbivudine—hepatitis B	0.00243	0.0141	CcSEcCtD
Pomalidomide—Blood creatinine increased—Entecavir—hepatitis B	0.00231	0.0135	CcSEcCtD
Pomalidomide—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00226	0.0131	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.00213	0.0124	CcSEcCtD
Pomalidomide—Pain in extremity—Telbivudine—hepatitis B	0.00203	0.0118	CcSEcCtD
Pomalidomide—Neutropenia—Entecavir—hepatitis B	0.002	0.0116	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Entecavir—hepatitis B	0.00198	0.0116	CcSEcCtD
Pomalidomide—Hyperglycaemia—Entecavir—hepatitis B	0.00193	0.0112	CcSEcCtD
Pomalidomide—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00189	0.011	CcSEcCtD
Pomalidomide—Renal failure—Entecavir—hepatitis B	0.00187	0.0109	CcSEcCtD
Pomalidomide—Thalidomide—TNF—hepatitis B	0.00187	0.235	CrCbGaD
Pomalidomide—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00183	0.0106	CcSEcCtD
Pomalidomide—Nasopharyngitis—Telbivudine—hepatitis B	0.00182	0.0106	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Entecavir—hepatitis B	0.0018	0.0105	CcSEcCtD
Pomalidomide—Muscular weakness—Telbivudine—hepatitis B	0.00179	0.0104	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00179	0.0104	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00176	0.0102	CcSEcCtD
Pomalidomide—Oedema peripheral—Entecavir—hepatitis B	0.00168	0.0098	CcSEcCtD
Pomalidomide—TNF—blood—hepatitis B	0.00168	0.248	CbGeAlD
Pomalidomide—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00165	0.00959	CcSEcCtD
Pomalidomide—Neutropenia—Telbivudine—hepatitis B	0.00164	0.00955	CcSEcCtD
Pomalidomide—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00164	0.00954	CcSEcCtD
Pomalidomide—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00163	0.00951	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00163	0.00949	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Lamivudine—hepatitis B	0.0016	0.00928	CcSEcCtD
Pomalidomide—Renal failure—Telbivudine—hepatitis B	0.00154	0.00895	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Telbivudine—hepatitis B	0.00153	0.00892	CcSEcCtD
Pomalidomide—Mental disorder—Entecavir—hepatitis B	0.0015	0.00872	CcSEcCtD
Pomalidomide—Malnutrition—Entecavir—hepatitis B	0.00149	0.00866	CcSEcCtD
Pomalidomide—Neuropathy—Lamivudine—hepatitis B	0.00148	0.00861	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Telbivudine—hepatitis B	0.00148	0.00861	CcSEcCtD
Pomalidomide—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00145	0.00845	CcSEcCtD
Pomalidomide—Back pain—Adefovir Dipivoxil—hepatitis B	0.0014	0.00817	CcSEcCtD
Pomalidomide—Connective tissue disorder—Telbivudine—hepatitis B	0.00138	0.00803	CcSEcCtD
Pomalidomide—Sepsis—Lamivudine—hepatitis B	0.00137	0.00796	CcSEcCtD
Pomalidomide—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00134	0.00781	CcSEcCtD
Pomalidomide—Leukopenia—Entecavir—hepatitis B	0.00133	0.00775	CcSEcCtD
Pomalidomide—Cough—Adefovir Dipivoxil—hepatitis B	0.00127	0.00737	CcSEcCtD
Pomalidomide—Mediastinal disorder—Telbivudine—hepatitis B	0.00127	0.00737	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00126	0.00732	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00123	0.00714	CcSEcCtD
Pomalidomide—Malnutrition—Telbivudine—hepatitis B	0.00122	0.00711	CcSEcCtD
Pomalidomide—Infection—Entecavir—hepatitis B	0.00121	0.00702	CcSEcCtD
Pomalidomide—Nervous system disorder—Entecavir—hepatitis B	0.00119	0.00693	CcSEcCtD
Pomalidomide—Back pain—Telbivudine—hepatitis B	0.00118	0.00688	CcSEcCtD
Pomalidomide—Skin disorder—Entecavir—hepatitis B	0.00118	0.00687	CcSEcCtD
Pomalidomide—Muscle spasms—Telbivudine—hepatitis B	0.00118	0.00684	CcSEcCtD
Pomalidomide—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00116	0.00676	CcSEcCtD
Pomalidomide—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00116	0.00675	CcSEcCtD
Pomalidomide—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00115	0.0067	CcSEcCtD
Pomalidomide—Insomnia—Entecavir—hepatitis B	0.0011	0.00639	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00108	0.00628	CcSEcCtD
Pomalidomide—Cough—Telbivudine—hepatitis B	0.00107	0.00621	CcSEcCtD
Pomalidomide—Dehydration—Lamivudine—hepatitis B	0.00106	0.00619	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Entecavir—hepatitis B	0.00105	0.0061	CcSEcCtD
Pomalidomide—Fatigue—Entecavir—hepatitis B	0.00105	0.00609	CcSEcCtD
Pomalidomide—Arthralgia—Telbivudine—hepatitis B	0.00104	0.00606	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00103	0.00602	CcSEcCtD
Pomalidomide—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00103	0.00599	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00102	0.00595	CcSEcCtD
Pomalidomide—Nasopharyngitis—Lamivudine—hepatitis B	0.00102	0.00595	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00101	0.00587	CcSEcCtD
Pomalidomide—Muscular weakness—Lamivudine—hepatitis B	0.00101	0.00587	CcSEcCtD
Pomalidomide—Nervous system disorder—Telbivudine—hepatitis B	0.000978	0.00569	CcSEcCtD
Pomalidomide—Thrombocytopenia—Telbivudine—hepatitis B	0.000977	0.00568	CcSEcCtD
Pomalidomide—Skin disorder—Telbivudine—hepatitis B	0.000969	0.00564	CcSEcCtD
Pomalidomide—Body temperature increased—Entecavir—hepatitis B	0.00096	0.00559	CcSEcCtD
Pomalidomide—Bronchitis—Lamivudine—hepatitis B	0.000951	0.00553	CcSEcCtD
Pomalidomide—Pancytopenia—Lamivudine—hepatitis B	0.000939	0.00546	CcSEcCtD
Pomalidomide—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000937	0.00545	CcSEcCtD
Pomalidomide—Neutropenia—Lamivudine—hepatitis B	0.000925	0.00538	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000909	0.00529	CcSEcCtD
Pomalidomide—Insomnia—Telbivudine—hepatitis B	0.000902	0.00525	CcSEcCtD
Pomalidomide—Hyperglycaemia—Lamivudine—hepatitis B	0.000892	0.00519	CcSEcCtD
Pomalidomide—Asthenia—Entecavir—hepatitis B	0.000871	0.00507	CcSEcCtD
Pomalidomide—Renal failure—Lamivudine—hepatitis B	0.000867	0.00504	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Lamivudine—hepatitis B	0.000864	0.00503	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Telbivudine—hepatitis B	0.000861	0.00501	CcSEcCtD
Pomalidomide—Fatigue—Telbivudine—hepatitis B	0.00086	0.00501	CcSEcCtD
Pomalidomide—Pain—Telbivudine—hepatitis B	0.000853	0.00497	CcSEcCtD
Pomalidomide—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00085	0.00495	CcSEcCtD
Pomalidomide—Pruritus—Adefovir Dipivoxil—hepatitis B	0.000838	0.00488	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Lamivudine—hepatitis B	0.000834	0.00485	CcSEcCtD
Pomalidomide—Epistaxis—Lamivudine—hepatitis B	0.000831	0.00484	CcSEcCtD
Pomalidomide—Diarrhoea—Entecavir—hepatitis B	0.000831	0.00484	CcSEcCtD
Pomalidomide—Feeling abnormal—Telbivudine—hepatitis B	0.000822	0.00478	CcSEcCtD
Pomalidomide—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.000811	0.00472	CcSEcCtD
Pomalidomide—Dizziness—Entecavir—hepatitis B	0.000803	0.00467	CcSEcCtD
Pomalidomide—CRBN—blood—hepatitis B	0.000803	0.119	CbGeAlD
Pomalidomide—Body temperature increased—Telbivudine—hepatitis B	0.000789	0.00459	CcSEcCtD
Pomalidomide—Connective tissue disorder—Lamivudine—hepatitis B	0.000778	0.00453	CcSEcCtD
Pomalidomide—Vomiting—Entecavir—hepatitis B	0.000772	0.00449	CcSEcCtD
Pomalidomide—Rash—Entecavir—hepatitis B	0.000766	0.00446	CcSEcCtD
Pomalidomide—Dermatitis—Entecavir—hepatitis B	0.000765	0.00445	CcSEcCtD
Pomalidomide—Headache—Entecavir—hepatitis B	0.000761	0.00443	CcSEcCtD
Pomalidomide—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000753	0.00438	CcSEcCtD
Pomalidomide—Rash—Adefovir Dipivoxil—hepatitis B	0.000747	0.00435	CcSEcCtD
Pomalidomide—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000746	0.00434	CcSEcCtD
Pomalidomide—Headache—Adefovir Dipivoxil—hepatitis B	0.000742	0.00432	CcSEcCtD
Pomalidomide—Nausea—Entecavir—hepatitis B	0.000721	0.0042	CcSEcCtD
Pomalidomide—CYP1A2—blood plasma—hepatitis B	0.00072	0.107	CbGeAlD
Pomalidomide—Asthenia—Telbivudine—hepatitis B	0.000716	0.00417	CcSEcCtD
Pomalidomide—Mediastinal disorder—Lamivudine—hepatitis B	0.000713	0.00415	CcSEcCtD
Pomalidomide—Chills—Lamivudine—hepatitis B	0.00071	0.00413	CcSEcCtD
Pomalidomide—Pruritus—Telbivudine—hepatitis B	0.000706	0.00411	CcSEcCtD
Pomalidomide—Nausea—Adefovir Dipivoxil—hepatitis B	0.000704	0.0041	CcSEcCtD
Pomalidomide—Malnutrition—Lamivudine—hepatitis B	0.000689	0.00401	CcSEcCtD
Pomalidomide—Diarrhoea—Telbivudine—hepatitis B	0.000683	0.00397	CcSEcCtD
Pomalidomide—Back pain—Lamivudine—hepatitis B	0.000666	0.00388	CcSEcCtD
Pomalidomide—Muscle spasms—Lamivudine—hepatitis B	0.000662	0.00385	CcSEcCtD
Pomalidomide—Dizziness—Telbivudine—hepatitis B	0.00066	0.00384	CcSEcCtD
Pomalidomide—Tremor—Lamivudine—hepatitis B	0.000645	0.00376	CcSEcCtD
Pomalidomide—Anaemia—Lamivudine—hepatitis B	0.000637	0.00371	CcSEcCtD
Pomalidomide—Vomiting—Telbivudine—hepatitis B	0.000634	0.00369	CcSEcCtD
Pomalidomide—Rash—Telbivudine—hepatitis B	0.000629	0.00366	CcSEcCtD
Pomalidomide—Dermatitis—Telbivudine—hepatitis B	0.000628	0.00366	CcSEcCtD
Pomalidomide—CRBN—liver—hepatitis B	0.000628	0.0929	CbGeAlD
Pomalidomide—Headache—Telbivudine—hepatitis B	0.000625	0.00364	CcSEcCtD
Pomalidomide—Vertigo—Lamivudine—hepatitis B	0.000619	0.0036	CcSEcCtD
Pomalidomide—Leukopenia—Lamivudine—hepatitis B	0.000617	0.00359	CcSEcCtD
Pomalidomide—Cough—Lamivudine—hepatitis B	0.000601	0.0035	CcSEcCtD
Pomalidomide—PTGS2—blood plasma—hepatitis B	0.000596	0.0883	CbGeAlD
Pomalidomide—Nausea—Telbivudine—hepatitis B	0.000593	0.00345	CcSEcCtD
Pomalidomide—Arthralgia—Lamivudine—hepatitis B	0.000587	0.00341	CcSEcCtD
Pomalidomide—Anxiety—Lamivudine—hepatitis B	0.000584	0.0034	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000582	0.00339	CcSEcCtD
Pomalidomide—Confusional state—Lamivudine—hepatitis B	0.000567	0.0033	CcSEcCtD
Pomalidomide—Infection—Lamivudine—hepatitis B	0.000559	0.00325	CcSEcCtD
Pomalidomide—Nervous system disorder—Lamivudine—hepatitis B	0.000551	0.00321	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lamivudine—hepatitis B	0.00055	0.0032	CcSEcCtD
Pomalidomide—Skin disorder—Lamivudine—hepatitis B	0.000546	0.00318	CcSEcCtD
Pomalidomide—Hyperhidrosis—Lamivudine—hepatitis B	0.000544	0.00316	CcSEcCtD
Pomalidomide—CYP3A4—blood plasma—hepatitis B	0.000521	0.0771	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000512	0.00298	CcSEcCtD
Pomalidomide—Insomnia—Lamivudine—hepatitis B	0.000509	0.00296	CcSEcCtD
Pomalidomide—Dyspnoea—Lamivudine—hepatitis B	0.000501	0.00292	CcSEcCtD
Pomalidomide—Decreased appetite—Lamivudine—hepatitis B	0.000489	0.00284	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000485	0.00283	CcSEcCtD
Pomalidomide—Fatigue—Lamivudine—hepatitis B	0.000485	0.00282	CcSEcCtD
Pomalidomide—Pain—Lamivudine—hepatitis B	0.000481	0.0028	CcSEcCtD
Pomalidomide—Constipation—Lamivudine—hepatitis B	0.000481	0.0028	CcSEcCtD
Pomalidomide—Feeling abnormal—Lamivudine—hepatitis B	0.000463	0.0027	CcSEcCtD
Pomalidomide—Body temperature increased—Lamivudine—hepatitis B	0.000444	0.00259	CcSEcCtD
Pomalidomide—Hypersensitivity—Lamivudine—hepatitis B	0.000414	0.00241	CcSEcCtD
Pomalidomide—Asthenia—Lamivudine—hepatitis B	0.000403	0.00235	CcSEcCtD
Pomalidomide—Pruritus—Lamivudine—hepatitis B	0.000398	0.00232	CcSEcCtD
Pomalidomide—Diarrhoea—Lamivudine—hepatitis B	0.000385	0.00224	CcSEcCtD
Pomalidomide—Dizziness—Lamivudine—hepatitis B	0.000372	0.00216	CcSEcCtD
Pomalidomide—ABCB1—blood plasma—hepatitis B	0.000369	0.0546	CbGeAlD
Pomalidomide—Vomiting—Lamivudine—hepatitis B	0.000357	0.00208	CcSEcCtD
Pomalidomide—Rash—Lamivudine—hepatitis B	0.000355	0.00206	CcSEcCtD
Pomalidomide—Dermatitis—Lamivudine—hepatitis B	0.000354	0.00206	CcSEcCtD
Pomalidomide—Headache—Lamivudine—hepatitis B	0.000352	0.00205	CcSEcCtD
Pomalidomide—Nausea—Lamivudine—hepatitis B	0.000334	0.00194	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR2—hepatitis B	0.000306	0.00345	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—hepatitis B	0.000305	0.00344	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNB1—hepatitis B	0.000304	0.00342	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GGT2—hepatitis B	0.000303	0.00342	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.0003	0.00338	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—NFKB1—hepatitis B	0.000299	0.00337	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—hepatitis B	0.000299	0.00337	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—hepatitis B	0.000297	0.00335	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DRB1—hepatitis B	0.000297	0.00334	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNA1—hepatitis B	0.000296	0.00334	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—hepatitis B	0.000294	0.00331	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—HSPA5—hepatitis B	0.000289	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	0.00028	0.00315	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —NFKB1—hepatitis B	0.000278	0.00313	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	0.000278	0.00313	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—hepatitis B	0.000278	0.00313	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNA2—hepatitis B	0.000276	0.00311	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD14—hepatitis B	0.000276	0.00311	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL6—hepatitis B	0.000275	0.0031	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—ALB—hepatitis B	0.000274	0.00309	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL10—hepatitis B	0.000273	0.00308	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—hepatitis B	0.000271	0.00306	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—NFKB1—hepatitis B	0.000269	0.00303	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—hepatitis B	0.000267	0.00301	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—hepatitis B	0.000265	0.00299	CbGpPWpGaD
Pomalidomide—CYP1A2—blood—hepatitis B	0.000264	0.039	CbGeAlD
Pomalidomide—TNF—Selenium Micronutrient Network—F2—hepatitis B	0.000262	0.00296	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—hepatitis B	0.000262	0.00295	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NFKB1—hepatitis B	0.00026	0.00293	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—NFKB1—hepatitis B	0.000256	0.00288	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GGT1—hepatitis B	0.000253	0.00285	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—CTNNB1—hepatitis B	0.000252	0.00284	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—hepatitis B	0.00025	0.00282	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—hepatitis B	0.00025	0.00282	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—hepatitis B	0.00025	0.00282	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.000249	0.00281	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—NFKB1—hepatitis B	0.000248	0.0028	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.000246	0.00277	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—NFKB1—hepatitis B	0.000244	0.00276	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—hepatitis B	0.000242	0.00273	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—NFKB1—hepatitis B	0.000241	0.00272	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CD14—hepatitis B	0.000237	0.00267	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—hepatitis B	0.000233	0.00263	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—hepatitis B	0.000231	0.00261	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—GGT1—hepatitis B	0.000225	0.00254	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—hepatitis B	0.000222	0.00251	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—hepatitis B	0.000222	0.00251	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—hepatitis B	0.000222	0.0025	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FAS—hepatitis B	0.000222	0.0025	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DPB1—hepatitis B	0.000219	0.00247	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—hepatitis B	0.000219	0.00247	CbGpPWpGaD
Pomalidomide—PTGS2—blood—hepatitis B	0.000219	0.0323	CbGeAlD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—hepatitis B	0.000218	0.00246	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—hepatitis B	0.000217	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—hepatitis B	0.000215	0.00243	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—hepatitis B	0.000214	0.00241	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDKN2A—hepatitis B	0.000211	0.00238	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—NFKB1—hepatitis B	0.000208	0.00235	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—hepatitis B	0.000208	0.00234	CbGpPWpGaD
Pomalidomide—CYP1A2—liver—hepatitis B	0.000206	0.0305	CbGeAlD
Pomalidomide—TNF—Spinal Cord Injury—NOS2—hepatitis B	0.000205	0.00231	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—hepatitis B	0.000204	0.0023	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.000202	0.00228	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—hepatitis B	0.000201	0.00226	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FASLG—hepatitis B	0.0002	0.00225	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—hepatitis B	0.000199	0.00224	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—NFKB1—hepatitis B	0.000199	0.00224	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—hepatitis B	0.000193	0.00218	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL10—hepatitis B	0.000193	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—hepatitis B	0.000193	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—hepatitis B	0.000193	0.00217	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.000192	0.00217	CbGpPWpGaD
Pomalidomide—CYP3A4—blood—hepatitis B	0.000191	0.0283	CbGeAlD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.00019	0.00214	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—hepatitis B	0.000189	0.00213	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—hepatitis B	0.000188	0.00211	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FASLG—hepatitis B	0.000187	0.00211	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.000186	0.00209	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—NFKB1—hepatitis B	0.000184	0.00207	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—AKR1B1—hepatitis B	0.000182	0.00206	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—hepatitis B	0.000181	0.00204	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GGT2—hepatitis B	0.000177	0.002	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—hepatitis B	0.000177	0.00199	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	0.000173	0.00195	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	0.000172	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—hepatitis B	0.000172	0.00194	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—hepatitis B	0.000172	0.00193	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—NFKB1—hepatitis B	0.000172	0.00193	CbGpPWpGaD
Pomalidomide—PTGS2—liver—hepatitis B	0.000171	0.0253	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.000169	0.00191	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—NFKB1—hepatitis B	0.000165	0.00186	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.000163	0.00184	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—F2—hepatitis B	0.000162	0.00183	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—hepatitis B	0.000162	0.00182	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—hepatitis B	0.000162	0.00182	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—hepatitis B	0.000161	0.00181	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NFKB1—hepatitis B	0.00016	0.0018	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—hepatitis B	0.000157	0.00177	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.000156	0.00176	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—hepatitis B	0.000153	0.00173	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—TGFB1—hepatitis B	0.00015	0.00169	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FASLG—hepatitis B	0.00015	0.00169	CbGpPWpGaD
Pomalidomide—CYP3A4—liver—hepatitis B	0.000149	0.0221	CbGeAlD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—NFKB1—hepatitis B	0.000147	0.00166	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—hepatitis B	0.000147	0.00165	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FAS—hepatitis B	0.000145	0.00163	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GGT1—hepatitis B	0.000143	0.00162	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—hepatitis B	0.000143	0.00161	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—hepatitis B	0.000143	0.00161	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—hepatitis B	0.000143	0.00161	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-A—hepatitis B	0.000142	0.0016	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—AKR1B1—hepatitis B	0.000141	0.00159	CbGpPWpGaD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—NFKB1—hepatitis B	0.000141	0.00159	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HNF4A—hepatitis B	0.00014	0.00158	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—hepatitis B	0.00014	0.00157	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GGT2—hepatitis B	0.000137	0.00154	CbGpPWpGaD
Pomalidomide—ABCB1—blood—hepatitis B	0.000135	0.02	CbGeAlD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—hepatitis B	0.000135	0.00152	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	0.000134	0.00151	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—hepatitis B	0.000133	0.0015	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.000132	0.00148	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—hepatitis B	0.000131	0.00147	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL6—hepatitis B	0.000131	0.00147	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—hepatitis B	0.00013	0.00147	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—NOS2—hepatitis B	0.000127	0.00143	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	0.000125	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—hepatitis B	0.000125	0.00141	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—hepatitis B	0.000125	0.00141	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—hepatitis B	0.000124	0.00139	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—hepatitis B	0.000123	0.00139	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—hepatitis B	0.000123	0.00139	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CDKN1A—hepatitis B	0.000122	0.00137	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—hepatitis B	0.000118	0.00133	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—hepatitis B	0.000117	0.00132	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—NFKB1—hepatitis B	0.000115	0.00129	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—hepatitis B	0.000109	0.00123	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—hepatitis B	0.000108	0.00122	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—hepatitis B	0.000108	0.00122	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP2A6—hepatitis B	0.000107	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—hepatitis B	0.000107	0.00121	CbGpPWpGaD
Pomalidomide—ABCB1—liver—hepatitis B	0.000106	0.0156	CbGeAlD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NFKB1—hepatitis B	0.000105	0.00118	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.000105	0.00118	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—hepatitis B	0.000104	0.00117	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—hepatitis B	0.000104	0.00117	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—hepatitis B	0.000102	0.00115	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—TGFB1—hepatitis B	0.000101	0.00114	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.000101	0.00114	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—hepatitis B	0.0001	0.00113	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NFKB1—hepatitis B	9.86e-05	0.00111	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	9.79e-05	0.0011	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	9.72e-05	0.0011	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—hepatitis B	9.72e-05	0.0011	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—hepatitis B	9.5e-05	0.00107	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—hepatitis B	9.22e-05	0.00104	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	9.17e-05	0.00103	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—hepatitis B	8.97e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	8.96e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	8.94e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	8.9e-05	0.001	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—hepatitis B	8.64e-05	0.000974	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—hepatitis B	8.44e-05	0.000951	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GGT1—hepatitis B	8.38e-05	0.000945	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP2A6—hepatitis B	8.29e-05	0.000934	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—hepatitis B	8.21e-05	0.000926	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—hepatitis B	8.21e-05	0.000925	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hepatitis B	8.1e-05	0.000913	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—hepatitis B	7.96e-05	0.000897	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—hepatitis B	7.6e-05	0.000856	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	7.56e-05	0.000853	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hepatitis B	7.56e-05	0.000853	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	7.41e-05	0.000835	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	7.41e-05	0.000835	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOBEC3G—hepatitis B	7.38e-05	0.000832	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SAG—hepatitis B	7.38e-05	0.000832	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—hepatitis B	7.21e-05	0.000813	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—hepatitis B	7.2e-05	0.000812	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	7.15e-05	0.000806	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	7.1e-05	0.0008	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—hepatitis B	6.76e-05	0.000762	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—hepatitis B	6.74e-05	0.00076	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—hepatitis B	6.58e-05	0.000742	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—hepatitis B	6.57e-05	0.00074	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GGT1—hepatitis B	6.47e-05	0.000729	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—hepatitis B	6.42e-05	0.000724	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—hepatitis B	6.29e-05	0.000709	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—hepatitis B	6.15e-05	0.000693	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	6.1e-05	0.000688	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	5.69e-05	0.000641	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	5.67e-05	0.000639	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKR1B1—hepatitis B	5.59e-05	0.00063	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—hepatitis B	5.55e-05	0.000625	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	5.54e-05	0.000625	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	5.53e-05	0.000623	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	5.5e-05	0.00062	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GGT2—hepatitis B	5.36e-05	0.000604	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—hepatitis B	5.08e-05	0.000572	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	4.58e-05	0.000517	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—hepatitis B	4.29e-05	0.000483	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	4.28e-05	0.000482	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NFKB1—hepatitis B	4.16e-05	0.000469	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	4.02e-05	0.000453	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKR1B1—hepatitis B	3.96e-05	0.000446	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	3.93e-05	0.000443	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	3.92e-05	0.000442	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	3.9e-05	0.00044	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GGT2—hepatitis B	3.8e-05	0.000428	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	3.77e-05	0.000425	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GOT2—hepatitis B	3.5e-05	0.000395	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—hepatitis B	3.47e-05	0.000391	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	3.25e-05	0.000366	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP2A6—hepatitis B	3.25e-05	0.000366	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	3.22e-05	0.000363	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKR1B1—hepatitis B	3.16e-05	0.000356	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	3.03e-05	0.000342	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GGT2—hepatitis B	3.03e-05	0.000342	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.03e-05	0.000341	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GOT1—hepatitis B	3.03e-05	0.000341	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GOT2—hepatitis B	2.93e-05	0.000331	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	2.67e-05	0.000302	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—hepatitis B	2.61e-05	0.000294	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GGT1—hepatitis B	2.53e-05	0.000286	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GOT1—hepatitis B	2.53e-05	0.000286	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKR1B1—hepatitis B	2.44e-05	0.000275	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GGT2—hepatitis B	2.34e-05	0.000264	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.31e-05	0.00026	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2A6—hepatitis B	2.3e-05	0.000259	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCR5—hepatitis B	2.26e-05	0.000255	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—hepatitis B	2.2e-05	0.000248	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GOT2—hepatitis B	2.08e-05	0.000235	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	2.04e-05	0.00023	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—hepatitis B	1.91e-05	0.000216	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2A6—hepatitis B	1.84e-05	0.000207	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GGT1—hepatitis B	1.8e-05	0.000202	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GOT1—hepatitis B	1.8e-05	0.000202	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.71e-05	0.000193	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GOT2—hepatitis B	1.66e-05	0.000187	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GOT1—hepatitis B	1.43e-05	0.000162	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GGT1—hepatitis B	1.43e-05	0.000162	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—hepatitis B	1.42e-05	0.00016	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2A6—hepatitis B	1.42e-05	0.00016	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—hepatitis B	1.35e-05	0.000152	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.31e-05	0.000147	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GOT2—hepatitis B	1.28e-05	0.000144	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—hepatitis B	1.26e-05	0.000142	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—hepatitis B	1.23e-05	0.000139	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—hepatitis B	1.23e-05	0.000138	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GGT1—hepatitis B	1.11e-05	0.000125	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GOT1—hepatitis B	1.11e-05	0.000125	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—hepatitis B	1.03e-05	0.000116	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—hepatitis B	1.02e-05	0.000115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—hepatitis B	9.55e-06	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—hepatitis B	7.67e-06	8.65e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—hepatitis B	7.63e-06	8.6e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—hepatitis B	7.29e-06	8.22e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—hepatitis B	5.89e-06	6.63e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—hepatitis B	5.82e-06	6.56e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—hepatitis B	4.49e-06	5.06e-05	CbGpPWpGaD
